Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status
暂无分享,去创建一个
A. Gupta | P. Vicini | P. Dennis | L. Roskos | R. Narwal | Xiaoping Jin | V. Dubois | Y. Ben | Yanan Zheng | P. Mukhopadhyay | Xuyang Song | P. Baverel | C. Jin
[1] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[2] R Bruno,et al. Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma , 2017, Clinical pharmacology and therapeutics.
[3] B. Meibohm,et al. Pharmacokinetics of Monoclonal Antibodies , 2017, CPT: pharmacometrics & systems pharmacology.
[4] M. Shah,et al. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] X. Zhao,et al. Assessment of nivolumab benefit–risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] D. D. de Alwis,et al. Evaluation of dosing strategy for pembrolizumab for oncology indications , 2017, Journal of Immunotherapy for Cancer.
[7] I Zineh,et al. Toward Greater Insights on Pharmacokinetics and Exposure–Response Relationships for Therapeutic Biologics in Oncology Drug Development , 2017, Clinical pharmacology and therapeutics.
[8] Y. Wang,et al. Association of Time‐Varying Clearance of Nivolumab With Disease Dynamics and Its Implications on Exposure Response Analysis , 2017, Clinical pharmacology and therapeutics.
[9] C. Langer,et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. , 2017, Lung cancer.
[10] A. Balar,et al. PD-1 and PD-L1 antibodies in cancer: current status and future directions , 2017, Cancer Immunology, Immunotherapy.
[11] P. Keegan,et al. U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab , 2017, Clinical Cancer Research.
[12] S. Agrawal,et al. Model‐Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors , 2016, CPT: pharmacometrics & systems pharmacology.
[13] G. Stephanopoulos,et al. Direct evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors , 2016, Nature Medicine.
[14] J. Stone,et al. Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors , 2016, CPT: pharmacometrics & systems pharmacology.
[15] P. Ascierto,et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Schlom,et al. Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with advanced solid tumors. , 2015 .
[17] J. Cortés,et al. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors , 2014, Cancer Chemotherapy and Pharmacology.
[18] Ben Tran,et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.
[19] R J Keizer,et al. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.
[20] C. Garnett,et al. The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making , 2013, Journal of clinical pharmacology.
[21] Andrew C. Hooker,et al. A Fast Method for Testing Covariates in Population PK/PD Models , 2011, The AAPS Journal.
[22] A. Olson,et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. , 2010, International journal of clinical pharmacology and therapeutics.
[23] S. Liao,et al. Population Pharmacokinetic Modeling of Ustekinumab, a Human Monoclonal Antibody Targeting IL‐12/23p40, in Patients With Moderate to Severe Plaque Psoriasis , 2009, Journal of clinical pharmacology.
[24] Rene Bruno,et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.
[25] E. Niclas Jonsson,et al. PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM , 2005, Comput. Methods Programs Biomed..
[26] E. Niclas Jonsson,et al. Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..
[27] Mats O. Karlsson,et al. Automated Covariate Model Building Within NONMEM , 1998, Pharmaceutical Research.
[28] P. Ascierto,et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[30] Stuart Moss,et al. Current Status and Future Directions , 2013 .
[31] David Hinkley,et al. Bootstrap Methods: Another Look at the Jackknife , 2008 .